Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871542 | 0.83 | CA2 (0.39) | CA2CA1ALDH1A1L3MBTL1CA9 | |
| SCHEMBL8374416 | 0.81 | CA2 (0.34) | CA2CA1ALDH1A1L3MBTL1 | |
| SCHEMBL17249650 | 0.79 | CA2 (0.33) | CA2CA1ALDH1A1L3MBTL1 | |
| SCHEMBL1509202 | 0.78 | TSHR (0.37) | CA2TSHRSMN1; SMN2CA1ALDH1A1 | |
| SCHEMBL5238163 | 0.76 | CA2 (0.40) | CA2TSHRCA1ALDH1A1L3MBTL1 | |
| SCHEMBL28553919 | 0.76 | TDP1 (0.35) | CA2CA1 | |
| Hydrogen Sulfide SCHEMBL8355994 | 0.76 | TSHR (0.36) | CA2TSHRCA1ALDH1A1 | |
| SCHEMBL5676976 | 0.75 | CA2 (0.33) | CA2CA1 | |
| SCHEMBL27800814 | 0.74 | PSEN1 (0.36) | CA2CA1 | |
| SCHEMBL1730503 | 0.74 | GAA (0.41) | TSHRSMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161280-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2019-08-22 | — | — | WO | claimed |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-114721222-A | Polymer composition and method for manufacturing semiconductor device | 台湾积体电路制造股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3752496-A1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES, INC. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-0679652-A1 | Process for preparing carbapenem compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-11-02 | — | — | EP | disclosed |
| US-5457111-A | Side effect reduction | ABBOTT LABORATORIES (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0642516-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-03-15 | — | — | EP | disclosed |
| EP-0638082-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994021642-A1 | MACROCYCLIC AMIDE AND UREA IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0642516-A4 | MACROCYCLIC IMMUNOMODULATORS. | ABBOTT LAB (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0638082-A4 | MACROCYCLIC IMMUNOMODULATORS. | ABBOTT LAB (US) | 1994-06-09 | — | — | EP | disclosed |
| WO-1993004680-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993004679-A1 | MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009904-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | CA2 891/4885TSHR 3048/4885CTH 1962/4885 |
| US-11117886-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | CA2 912/4885TSHR 3015/4885CTH 2045/4885 |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | CA2 912/4885TSHR 3015/4885CTH 2045/4885 |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | CA2 891/4885TSHR 3048/4885CTH 1962/4885 |
| US-20200369647-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | CYP11A1, CYP11B1, CYP11B2 | CA2 912/4885TSHR 3015/4885CTH 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.